Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus PD-1 antibody for unresectable intrahepatic cholangiocarcinoma
NCT03779100Phase 2Suspended
- Sponsor
- Shiming Biotech
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Shiming Biotech. Started Dec 2018; status: suspended.
02
Drugs
lenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03779100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779100.